"The NICHD study clearly demonstrated the superiority of microarrays over traditional
karyotyping," said Jim Goldberg, MD of San Francisco Perinatal Associates.$ "Due to the strength of the data in that study, we now counsel patients on the availability ...
[Published Stockwatch - Jun 18 2013]